BiotechTube

Ertapenem

Phase 2/3Completed
0 views this week 0 watching💤 Quiet
Interest: 38/100
38
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

SURGICAL SITE INFECTION

Conditions

SURGICAL SITE INFECTION

Trial Timeline

Dec 1, 2010 → Oct 1, 2011

NCT ID
NCT01203046

About Ertapenem

Ertapenem is a phase 2/3 stage product being developed by Merck for SURGICAL SITE INFECTION. The current trial status is completed. This product is registered under clinical trial identifier NCT01203046. Target conditions include SURGICAL SITE INFECTION.

What happened to similar drugs?

7 of 20 similar drugs in SURGICAL SITE INFECTION were approved

Approved (7) Terminated (5) Active (10)
✅Epoetin alfa + Standard of CareJohnson & JohnsonApproved
✅ErtapenemMerckApproved
✅Sugammadex + RocuroniumMerckApproved
✅Deep neuromuscular blockMerckApproved
✅RocuroniumMerckApproved
✅parecoxib/valdecoxibPfizerApproved
✅Tranexamic acid + Standard of CarePfizerApproved

Hype Score Breakdown

Clinical
15
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (5)

NCT IDPhaseStatus
NCT02041767ApprovedCompleted
NCT01159379ApprovedUNKNOWN
NCT01203046Phase 2/3Completed
NCT01173068Pre-clinicalUNKNOWN
NCT00939952ApprovedCompleted

Competing Products

20 competing products in SURGICAL SITE INFECTION

See all competitors
ProductCompanyStageHype Score
DFA-02 Antibiotic Gel + DFA-02 Placebo GelDr. Reddy's LaboratoriesPhase 2
32
DFA-02 + PlaceboDr. Reddy's LaboratoriesPhase 1/2
29
CelecoxibAstellas PharmaPre-clinical
26
Nivolumab + EverolimusOno PharmaceuticalPhase 3
40
Epoetin alfa + Standard of CareJohnson & JohnsonApproved
35
HR021618 + HR021618 + PlaceboJiangsu Hengrui MedicinePhase 2
31
SHR0410 Injection + Placebo for SHR0410 InjectionJiangsu Hengrui MedicinePhase 2
27
ErtapenemMerckApproved
43
Sugammadex + RocuroniumMerckApproved
43
Deep neuromuscular blockMerckApproved
43
RocuroniumMerckApproved
43
Sugammadex + Neostigmine + GlycopyrrolateMerckPhase 3
40
Ecallantide + PlaceboMerckPhase 2
27
Amicidin-β topical solution - 15 mL + Amicidin-β topical solution - 50 mL + Standard of Care (SOC)Novo NordiskPhase 1
36
Insulin infusion with a goalNovo NordiskPhase 3
40
parecoxib/valdecoxibPfizerApproved
35
Tranexamic acid + Standard of CarePfizerApproved
43
Ibuprofen 250 mg / Acetaminophen 500 mg + Ibuprofen 250 mg + Acetaminophen 650 mg + PlaceboPfizerPhase 3
40
valdecoxib + valdecoxib/placebo + placeboPfizerPhase 3
40
PF-04531083 + PF-04531083 + IbuprofenPfizerPhase 2
27